{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T23:25:23Z","timestamp":1772234723143,"version":"3.50.1"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012542","name":"Sichuan Province Science and Technology Support Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background\/Aims<\/jats:title><jats:p>Currently, glycemic variability has more deleterious effects than sustained hyperglycemia and is closely associated with acute and chronic complications of diabetes. Reducing glycemic excursion is becoming another vital goal\u00a0of glycemic control in clinical practice. This study aimed to determine whether insulin degludec (IDeg) or insulin glargine (IGla) was more beneficial for reducing glycemic\u00a0fluctuations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>This research was constructed according to the PRISMA guidelines. We searched eight databases and ClinicalTrials.gov from their inception to 30 November 2021. All randomized controlled trials comparing the efficacy of glucose variability between IDeg and IGla in diabetic patients were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Fourteen trials with 8,683 participants were included. In patients with T1DM, IDeg was associated with a lower mean (MD: \u221216.25, 95% CI \u221229.02 to \u22123.07, P = 0.01) and standard deviation (P = 0.03) compared to IGla in fasting blood glucose (FBG); in people with T2DM, IDeg was related to a lower mean of FBG versus insulin glargine 100 U\/ml (IGla100) (P &amp;lt;0.001) and had a more extended time in the range (TIR) than IGla100 (SMD: 0.15, 95% CI 0.02 to 0.27, P = 0.02) but not longer than insulin glargine 300 U\/ml (IGla300). Moreover, IDeg had a lower coefficient of variation of FBG than IGla (P = 0.0254). For other indicators of glycemic variability, namely, standard deviation of blood glucose for 24 h, the mean of 24-h blood glucose, mean amplitude of glycemic excursion, the coefficient of variation for 24 h, the mean of daily differences, area under the glucose curve, and M-value, no significant differences were identified between IDeg and IGla, regardless of T1DM or T2DM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Based on the current studies, there was comparable efficacy between IDeg and IGla from multiple aspects of glycemic variability, regardless of T1DM or T2DM. However, IDeg may be superior to IGla in reducing FBG variability in T1DM and T2DM. Nonetheless, due to the limitations of the original studies, it is still unclear whether IDeg is superior to both IGla100 and IGla300. In T2DM, IDeg had more extended TIR than IGla100 but not longer than IGla300. Additionally, more well-designed randomized controlled trials comparing IDeg with IGla300 for different indicators of glycemic variability are still warranted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p>PROSPERO, CRD42021283203.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.890090","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T11:09:35Z","timestamp":1654254575000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.3389","volume":"13","author":[{"given":"Yunjiao","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2018.02.023","article-title":"Idf Diabetes Atlas: Global Estimates of Diabetes Prevalence for 2017 and Projections for 2045","volume":"138","author":"Cho","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"B2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12933-015-0275-3","article-title":"Association Between Blood Glucose Variability and Coronary Plaque Instability in Patients With Acute Coronary Syndromes","volume":"14","author":"Okada","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.14.1681","article-title":"Activation of Oxidative Stress by Acute Glucose Fluctuations Compared With Sustained Chronic Hyperglycemia in Patients With Type 2 Diabetes","volume":"295","author":"Monnier","year":"2006","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2337\/db12-1396","article-title":"Glucose Variability","volume":"62","author":"Service","year":"2013","journal-title":"Diabetes"},{"key":"B5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12933-020-01085-6","article-title":"Glycemic Variability: Adverse Clinical Outcomes and How to Improve It","volume":"19","author":"Zhou","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0199","article-title":"Impact of Visit-To-Visit Glycemic Variability on the Risks of Macrovascular and Microvascular Events and All-Cause Mortality in Type 2 Diabetes: The ADVANCE Trial","volume":"37","author":"Hirakawa","year":"2014","journal-title":"Diabetes Care"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-01893-1","article-title":"Prognostic Impact of Visit-To-Visit Glycemic Variability on the Risks of Major Adverse Cardiovascular Outcomes and Hypoglycemia in Patients With Different Glycemic Control and Type 2 Diabetes","volume":"64","author":"Sun","year":"2019","journal-title":"Endocrine"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0677-0","article-title":"Long-Term Visit-To-Visit Glycemic Variability as Predictor of Micro- and Macrovascular Complications in Patients With Type 2 Diabetes: The Rio De Janeiro Type 2 Diabetes Cohort Study","volume":"17","author":"Cardoso","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12933-018-0761-5","article-title":"Glycemic Variability Determined With a Continuous Glucose Monitoring System can Predict Prognosis After Acute Coronary Syndrome","volume":"17","author":"Takahashi","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12933-019-0975-1","article-title":"Visit-To-Visit Variability of Glycemia and Vascular Complications: The Hoorn Diabetes Care System Cohort","volume":"18","author":"Slieker","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1288614","article-title":"Insulin Glargine 300 Units\/mL: A Guide for Healthcare Professionals Involved in the Management of Diabetes","volume":"33","author":"Strong","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1668","article-title":"The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-Week, Randomized, Open-Label, Parallel-Group, Treat-To-Target Trial in Individuals With Type 2 Diabetes","volume":"36","author":"Meneghini","year":"2013","journal-title":"Diabetes Care"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2016.07.019","article-title":"Comparison of Glycemic Variability in Japanese Patients With Type 1 Diabetes Receiving Insulin Degludec Versus Insulin Glargine Using Continuous Glucose Monitoring: A Randomized, Cross-Over, Pilot Study","volume":"120","author":"Onda","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ18-0309","article-title":"Efficacy and Safety of Insulin Degludec U100 and Insulin Glargine U100 in Combination With Meal-Time Bolus Insulin in Hospitalized Patients With Type 2 Diabetes: An Open-Label, Randomized Controlled Study","volume":"66","author":"Suzuki","year":"2019","journal-title":"Endocr J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.diabet.2017.10.001","article-title":"Morning Administration of 0.4U\/Kg\/Day Insulin Glargine 300u\/Ml Provides Less Fluctuating 24-Hour Pharmacodynamics and More Even Pharmacokinetic Profiles Compared With Insulin Degludec 100u\/Ml in Type 1 Diabetes","volume":"44","author":"Bailey","year":"2018","journal-title":"Diabetes Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12938","article-title":"Insulin Degludec: Lower Day-To-Day and Within-Day Variability in Pharmacodynamic Response Compared With Insulin Glargine 300 U\/mL in Type 1 Diabetes","volume":"19","author":"Heise","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3648-y","article-title":"Effects of Insulin Degludec and Insulin Glargine on Day-To-Day Fasting Plasma Glucose Variability in Individuals With Type 1 Diabetes: A Multicentre, Randomised, Crossover Study","volume":"58","author":"Nakamura","year":"2015","journal-title":"Diabetologia"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0269-0","article-title":"Glycemic Variability in Type 1 Diabetes Compared With Degludec and Glargine on the Morning Injection: An Open-Label Randomized Controlled Trial","volume":"8","author":"Iga","year":"2017","journal-title":"Diabetes Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2017.06.007","article-title":"Effect of Insulin Degludec Versus Insulin Glargine on Glycemic Control and Daily Fasting Blood Glucose Variability in Insulin-Naive Japanese Patients With Type 2 Diabetes: I'D GOT Trial","volume":"130","author":"Aso","year":"2017","journal-title":"Diabetes Res Clin Pr"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-018-1107-1","article-title":"Comparative Safety and Efficacy of Insulin Degludec With Insulin Glargine in Type 2 and Type 1 Diabetes: A Meta-Analysis of Randomized Controlled Trials","volume":"55","author":"Zhang","year":"2018","journal-title":"Acta Diabetol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8726046","article-title":"Efficacy and Safety of Insulin Degludec Versus Insulin Glargine: A Systematic Review and Meta-Analysis of Fifteen Clinical Trials","volume":"2018","author":"Liu","year":"2018","journal-title":"Int J Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's Tool for Assessing Risk of Bias in Randomised Trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the Sample Mean and Standard Deviation From the Sample Size, Median, Range and\/or Interquartile Range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res methodol"},{"key":"B25","article-title":"Effect of Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Patients With Type 2 Diabetes Mellitus","year":"2015"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14504","article-title":"Effect of Insulin Degludec Versus Insulin Glargine U100 on Time in Range: Switch Pro, a Crossover Study of Basal Insulin-Treated Adults With Type 2 Diabetes and Risk Factors for Hypoglycaemia","volume":"23","author":"Goldenberg","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14161","article-title":"Effects of Insulin Degludec and Insulin Glargine U300 on Glycaemic Stability in Individuals With Type 1 Diabetes: A Multicentre, Randomized Controlled Crossover Study","volume":"22","author":"Miura","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12884","article-title":"Efficacy and Safety of Insulin Glargine 300 U\/mL vs Insulin Degludec in Patients With Type 2 Diabetes: A Randomized, Open-Label, Cross-Over Study Using Continuous Glucose Monitoring Profiles","volume":"10","author":"Kawaguchi","year":"2019","journal-title":"J Diabetes Investig"},{"key":"B29","first-page":"19","article-title":"Comparison of Clinical Efficacy of Insulin Degludec and Insulin Glargine","volume":"10","author":"Ye","year":"2020","journal-title":"J Front Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.15975\/j.cnki.gsyy.2019.09.008","article-title":"Effect of Insulin Aspart Combined With Insulin Degludec or Insulin Glargine in the Treatment of Newly Diagnosed Type 2 Diabetes","volume":"38","author":"Tian","year":"2019","journal-title":"Gansu Medical Journal"},{"key":"B31","article-title":"Effect Comparison of Insulin Aspart Combined With Insulin Glargine or Insulin Degludec on Type 2 Diabetes Mellitus","volume":"19","author":"Han","year":"2020","journal-title":"Women\u2019s Health Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12894","article-title":"Comparison of Insulin Glargine 300 U\/mL and Insulin Degludec Using Flash Glucose Monitoring: A Randomized Cross-Over Study","volume":"10","author":"Yamabe","year":"2019","journal-title":"J Diabetes Investig"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615692","article-title":"Efficacy and Safety of Degludec Versus Glargine in Type 2 Diabetes","volume":"377","author":"Marso","year":"2017","journal-title":"New Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.14.1707","article-title":"Glycemic Variability: A Hemoglobin A1c-Independent Risk Factor for Diabetic Complications","volume":"295","author":"Brownlee M and Hirsch","year":"2006","journal-title":"JAMA"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/er.2009-0021","article-title":"Glucose Variability; Does it Matter","volume":"31","author":"Siegelaar","year":"2010","journal-title":"Endocr Rev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2337\/db12-1610","article-title":"Glucose Variability: Where it is Important and How to Measure it","volume":"62","author":"DeVries","year":"2013","journal-title":"Diabetes"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2898","article-title":"Glycemic Variability and Diabetes Complications: Does It Matter? Of Course It Does","volume":"38","author":"Hirsch","year":"2015","journal-title":"Diabetes Care"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-013-0096-7","article-title":"A Comparison of the Steady-State Pharmacokinetic and Pharmacodynamic Profiles of 100 and 200 U\/mL Formulations of Ultra-Long-Acting Insulin Degludec","volume":"33","author":"Korsatko","year":"2013","journal-title":"Clin Drug Invest"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01638.x","article-title":"Ultra-Long-Acting Insulin Degludec has a Flat and Stable Glucose-Lowering Effect in Type 2 Diabetes","volume":"14","author":"Heise","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0006","article-title":"New Insulin Glargine 300 Units \u00b7 mL-1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units \u00b7 Ml-1","volume":"38","author":"Becker","year":"2015","journal-title":"Diabetes Care"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12415","article-title":"Single-Dose New Insulin Glargine 300\u2009U\/Ml Provides Prolonged, Stable Glycaemic Control in Japanese and European People With Type 1 Diabetes","volume":"17","author":"Shiramoto","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01627.x","article-title":"Insulin Degludec: Four Times Lower Pharmacodynamic Variability Than Insulin Glargine Under Steady-State Conditions in Type 1 Diabetes","volume":"14","author":"Heise","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)60205-0","article-title":"Insulin Degludec, an Ultra-Longacting Basal Insulin, Versus Insulin Glargine in Basal-Bolus Treatment With Mealtime Insulin Aspart in Type 2 Diabetes (BEGIN Basal-Bolus Type 2): A Phase 3, Randomised, Open-Label, Treat-To-Target Non-Inferiority Trial","volume":"379","author":"Garber","year":"2012","journal-title":"Lancet"},{"key":"B44","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s00125-017-4423-z","article-title":"Day-To-Day Fasting Glycaemic Variability in DEVOTE: Associations With Severe Hypoglycaemia and Cardiovascular Outcomes (DEVOTE 2)","volume":"61","author":"Zinman","year":"2018","journal-title":"Diabetologia"},{"key":"B45","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jama.2017.7117","article-title":"Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial","volume":"318","author":"Wysham","year":"2017","journal-title":"JAMA"},{"key":"B46","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jama.2017.7115","article-title":"Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial","volume":"318","author":"Lane","year":"2017","journal-title":"JAMA"},{"key":"B47","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s00125-019-05080-9","article-title":"Risk of Hypoglycaemia With Insulin Degludec Versus Insulin Glargine U300 in Insulin-Treated Patients With Type 2 Diabetes: The Randomised, Head-To-Head CONCLUDE Trial","volume":"63","author":"Philis-Tsimikas","year":"2020","journal-title":"Diabetologia"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13616","article-title":"A Comparative Effectiveness Study of Degludec and Insulin Glargine 300\u2009U\/Ml in Insulin-Na\u00efve Patients With Type 2 Diabetes","volume":"21","author":"Tibaldi","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.3","article-title":"Metrics for Glycaemic Control - From HbA(1c) to Continuous Glucose Monitoring","volume":"13","author":"Kovatchev","year":"2017","journal-title":"Nat Rev Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.890090\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T11:09:44Z","timestamp":1654254584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.890090\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":49,"alternative-id":["10.3389\/fendo.2022.890090"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.890090","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]},"article-number":"890090"}}